Over the past decade, AbbVie's shares have increased by 353.3%, or 16.3% annually, with dividends reinvested. That's ...

Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look ...

AbbVie and Genmab’s epcoritamab has shown promise as part of a combination treatment for relapsed or refractory follicular ...

AbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...

The expansion is part of AbbVie’s larger $10 billion commitment to U.S. investment in the face of Trump’s tariff threats.

Construction on the site will begin in the fall and is expected to be finished by 2027. North Chicago is already home to ...

AbbVie (NYSE: ABBV) announced today that it has completed its acquisition of Capstan Therapeutics. With the completion of the acquisition, Capstan is now a part of AbbVie.

As pharma companies big and small play up their U.S. investment plans during the second Trump administration, the particulars ...

The promising results, along with a separate FDA decision, could signal a major expansion of the use of the two companies' ...

AbbVie will invest $195 million in its North Chicago, Illinois, manufacturing plant to expand domestic API production in the ...

AbbVie will invest $195M to expand API manufacturing at its North Chicago plant, boosting U.S. pharmaceutical innovation, ...

AbbVie is investing $195m to strengthen domestic API production, with the expansion of its manufacturing plant in North ...